CAR T-cell therapy as a definitive consolidation for older adults with B-ALL in first complete remission.

Blood AdvSep 6, 2026
Clinical ResearchHematologyOncology (Medical)Open access

Ibrahim Aldoss, Lior Goldberg, Jianying Zhang et al.

✦ AI-curated · Sources linked

In 30 seconds

This phase 1 clinical trial evaluated the safety and efficacy of CD19 CAR T-cell therapy as consolidation treatment in older adults (≥55 years) with B-cell acute lymphoblastic leukemia (B-ALL) in first complete remission. Eighteen patients were treated, showing no significant toxicities. The estimated 18-month event-free survival was 84%, and overall survival was 100%.

Key findings

  • No dose-limiting toxicities or grade ≥2 cytokine release syndrome were observed.
  • Estimated 18-month event-free survival was 84%.
  • Overall survival at 18 months was 100%.
  • CAR T cells expanded in both blood and cerebrospinal fluid.

Why it matters

The study highlights the potential of CAR T-cell therapy as a safe and effective consolidation treatment for older adults with B-ALL in first complete remission, suggesting a promising avenue for improving patient outcomes.

Source

PubMed · PMID 42341322Free full text on PubMed Central

Published in Blood Adv. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Hematology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.